EMEA-000170-PIP02-10-M03
Key facts
Invented name |
Revolade
|
Active substance |
Eltrombopag
|
Therapeutic area |
Haematology-Hemostaseology
|
Decision number |
P/0070/2019
|
PIP number |
EMEA-000170-PIP02-10-M03
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of secondary thrombocytopenia
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|